Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy

Lucio Catalano, Claudia Andretta, Leonardo Pace, Silvana Del Vecchio, Rosa Fonti, Giuditta Pollio, Barbara Salvatore, Carmine Esposito, Marco Salvatore, Bruno Rotoli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Solitary plasmacytoma (SP) is a rare clinical variant of malignant plasma cell proliferation; radiotherapy with or without local surgery is the treatment of choice. However, the disease progresses in a significant proportion of patients, requiring chemotherapy. The prognostic uncertainty is partly based on difficulties in disease monitoring. Tc99m-sestaMIBI is absorbed in various malignant tissues, including bone marrow in multiple myeloma lesions. We have investigated the ability of Tc99m-sestaMIBI scintigraphy to monitor patients with SP. Eight patients with SP were followed-up from June 1997 to May 2003. After induction treatment, which always included local procedures (surgery, radiotherapy), often followed by chemotherapy, the patients were monitored by physical examination, X-ray, CT scans, MRI, and biochemical parameters, at regular intervals. Tc99m-sestaMIBI scintigraphy was also performed repetitively in all patients. There was a strong correlation between standard procedures of follow-up and Tc99-sestaMIBI scan in 15/17 evaluations: tracer uptake was always normal in remission, decreased uptake was detected after partial remission and focal uptake was demonstrated in two patients at relapse. One false negative was observed at diagnosis and another during the follow-up. In this study, the sensitivity of Tc99m-sestaMIBI scintigraphy was 80%. The results of this study suggest that Tc99m-sestaMIBI scintigraphy is a useful tool for the follow-up of patients with SP.

Original languageEnglish
Pages (from-to)329-334
Number of pages6
JournalHAEMA
Volume7
Issue number3
Publication statusPublished - Jul 2004

Fingerprint

Plasmacytoma
Radionuclide Imaging
Radiotherapy
Drug Therapy
X Ray Computed Tomography
Plasma Cells
Multiple Myeloma
Physical Examination
Uncertainty
Bone Marrow
Cell Proliferation
Recurrence
Therapeutics

Keywords

  • Myeloma
  • Scintigraphy
  • Solitary plasmacytoma
  • Tc99m-sestaMIBI

ASJC Scopus subject areas

  • Hematology

Cite this

Catalano, L., Andretta, C., Pace, L., Del Vecchio, S., Fonti, R., Pollio, G., ... Rotoli, B. (2004). Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy. HAEMA, 7(3), 329-334.

Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy. / Catalano, Lucio; Andretta, Claudia; Pace, Leonardo; Del Vecchio, Silvana; Fonti, Rosa; Pollio, Giuditta; Salvatore, Barbara; Esposito, Carmine; Salvatore, Marco; Rotoli, Bruno.

In: HAEMA, Vol. 7, No. 3, 07.2004, p. 329-334.

Research output: Contribution to journalArticle

Catalano, L, Andretta, C, Pace, L, Del Vecchio, S, Fonti, R, Pollio, G, Salvatore, B, Esposito, C, Salvatore, M & Rotoli, B 2004, 'Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy', HAEMA, vol. 7, no. 3, pp. 329-334.
Catalano L, Andretta C, Pace L, Del Vecchio S, Fonti R, Pollio G et al. Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy. HAEMA. 2004 Jul;7(3):329-334.
Catalano, Lucio ; Andretta, Claudia ; Pace, Leonardo ; Del Vecchio, Silvana ; Fonti, Rosa ; Pollio, Giuditta ; Salvatore, Barbara ; Esposito, Carmine ; Salvatore, Marco ; Rotoli, Bruno. / Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy. In: HAEMA. 2004 ; Vol. 7, No. 3. pp. 329-334.
@article{254dd3ba8e1c46c4b1efb141c5cdeb97,
title = "Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy",
abstract = "Solitary plasmacytoma (SP) is a rare clinical variant of malignant plasma cell proliferation; radiotherapy with or without local surgery is the treatment of choice. However, the disease progresses in a significant proportion of patients, requiring chemotherapy. The prognostic uncertainty is partly based on difficulties in disease monitoring. Tc99m-sestaMIBI is absorbed in various malignant tissues, including bone marrow in multiple myeloma lesions. We have investigated the ability of Tc99m-sestaMIBI scintigraphy to monitor patients with SP. Eight patients with SP were followed-up from June 1997 to May 2003. After induction treatment, which always included local procedures (surgery, radiotherapy), often followed by chemotherapy, the patients were monitored by physical examination, X-ray, CT scans, MRI, and biochemical parameters, at regular intervals. Tc99m-sestaMIBI scintigraphy was also performed repetitively in all patients. There was a strong correlation between standard procedures of follow-up and Tc99-sestaMIBI scan in 15/17 evaluations: tracer uptake was always normal in remission, decreased uptake was detected after partial remission and focal uptake was demonstrated in two patients at relapse. One false negative was observed at diagnosis and another during the follow-up. In this study, the sensitivity of Tc99m-sestaMIBI scintigraphy was 80{\%}. The results of this study suggest that Tc99m-sestaMIBI scintigraphy is a useful tool for the follow-up of patients with SP.",
keywords = "Myeloma, Scintigraphy, Solitary plasmacytoma, Tc99m-sestaMIBI",
author = "Lucio Catalano and Claudia Andretta and Leonardo Pace and {Del Vecchio}, Silvana and Rosa Fonti and Giuditta Pollio and Barbara Salvatore and Carmine Esposito and Marco Salvatore and Bruno Rotoli",
year = "2004",
month = "7",
language = "English",
volume = "7",
pages = "329--334",
journal = "HAEMA",
issn = "1108-2682",
publisher = "Haema Journal",
number = "3",

}

TY - JOUR

T1 - Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy

AU - Catalano, Lucio

AU - Andretta, Claudia

AU - Pace, Leonardo

AU - Del Vecchio, Silvana

AU - Fonti, Rosa

AU - Pollio, Giuditta

AU - Salvatore, Barbara

AU - Esposito, Carmine

AU - Salvatore, Marco

AU - Rotoli, Bruno

PY - 2004/7

Y1 - 2004/7

N2 - Solitary plasmacytoma (SP) is a rare clinical variant of malignant plasma cell proliferation; radiotherapy with or without local surgery is the treatment of choice. However, the disease progresses in a significant proportion of patients, requiring chemotherapy. The prognostic uncertainty is partly based on difficulties in disease monitoring. Tc99m-sestaMIBI is absorbed in various malignant tissues, including bone marrow in multiple myeloma lesions. We have investigated the ability of Tc99m-sestaMIBI scintigraphy to monitor patients with SP. Eight patients with SP were followed-up from June 1997 to May 2003. After induction treatment, which always included local procedures (surgery, radiotherapy), often followed by chemotherapy, the patients were monitored by physical examination, X-ray, CT scans, MRI, and biochemical parameters, at regular intervals. Tc99m-sestaMIBI scintigraphy was also performed repetitively in all patients. There was a strong correlation between standard procedures of follow-up and Tc99-sestaMIBI scan in 15/17 evaluations: tracer uptake was always normal in remission, decreased uptake was detected after partial remission and focal uptake was demonstrated in two patients at relapse. One false negative was observed at diagnosis and another during the follow-up. In this study, the sensitivity of Tc99m-sestaMIBI scintigraphy was 80%. The results of this study suggest that Tc99m-sestaMIBI scintigraphy is a useful tool for the follow-up of patients with SP.

AB - Solitary plasmacytoma (SP) is a rare clinical variant of malignant plasma cell proliferation; radiotherapy with or without local surgery is the treatment of choice. However, the disease progresses in a significant proportion of patients, requiring chemotherapy. The prognostic uncertainty is partly based on difficulties in disease monitoring. Tc99m-sestaMIBI is absorbed in various malignant tissues, including bone marrow in multiple myeloma lesions. We have investigated the ability of Tc99m-sestaMIBI scintigraphy to monitor patients with SP. Eight patients with SP were followed-up from June 1997 to May 2003. After induction treatment, which always included local procedures (surgery, radiotherapy), often followed by chemotherapy, the patients were monitored by physical examination, X-ray, CT scans, MRI, and biochemical parameters, at regular intervals. Tc99m-sestaMIBI scintigraphy was also performed repetitively in all patients. There was a strong correlation between standard procedures of follow-up and Tc99-sestaMIBI scan in 15/17 evaluations: tracer uptake was always normal in remission, decreased uptake was detected after partial remission and focal uptake was demonstrated in two patients at relapse. One false negative was observed at diagnosis and another during the follow-up. In this study, the sensitivity of Tc99m-sestaMIBI scintigraphy was 80%. The results of this study suggest that Tc99m-sestaMIBI scintigraphy is a useful tool for the follow-up of patients with SP.

KW - Myeloma

KW - Scintigraphy

KW - Solitary plasmacytoma

KW - Tc99m-sestaMIBI

UR - http://www.scopus.com/inward/record.url?scp=4043074828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043074828&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 329

EP - 334

JO - HAEMA

JF - HAEMA

SN - 1108-2682

IS - 3

ER -